Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomea Fusion Inc (NQ: BMEA )

9.720 +0.170 (+1.78%)
Streaming Delayed Price Updated: 11:50 AM EST, Feb 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,086
Open 9.530
Bid (Size) 9.510 (3)
Ask (Size) 9.730 (1)
Prev. Close 9.550
Today's Range 9.303 - 9.740
52wk Range 2.840 - 14.20
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Why Shares of Biomea Fusion Jumped This Week
The company launched its second trial this year for its lead therapy. 
Via The Motley Fool
Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors
From Biomea Fusion, Inc.
Via Globe NewsWire

Performance

YTD
+14.62%
+14.62%
1 Month
+14.62%
+14.62%
3 Month
-14.06%
-14.06%
6 Month
-11.23%
-11.23%
1 Year
+48.17%
+48.17%

More News

Read More
Analyst Expectations for Biomea Fusion's Future
Via Benzinga
US Stocks Edge Lower; Bank of America Profit Tops Views
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Biomea Fusion: Q2 Earnings Insights
Via Benzinga
Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones
From Biomea Fusion, Inc.
Via Globe NewsWire
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (COVALENT-111) Study of BMF-219
From Biomea Fusion, Inc.
Via Globe NewsWire
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes
From Biomea Fusion, Inc.
Via Globe NewsWire
Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date
From Biomea Fusion, Inc.
Via Globe NewsWire
Is Ardelyx is A Buy After Slip in Early 2022
Via MarketBeat
Exposures Product Safety
Biomea Fusion to Participate in Piper Sandler 34th Annual Healthcare Conference
From Biomea Fusion, Inc.
Via Globe NewsWire
Biomea Fusion Reports Third Quarter 2022 Financial Results and Business Highlights
From Biomea Fusion, Inc.
Via Globe NewsWire
Biomea Fusion to Present Preclinical Data for BMF-500, an Investigational Oral Covalent FLT3 Inhibitor, at the 64th American Society of Hematology (ASH) Annual Meeting
From Biomea Fusion, Inc.
Via Globe NewsWire
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219
From Biomea Fusion, Inc.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Via Benzinga
Biomea Fusion Announces First Patient Dosed with Chronic Lymphocytic Leukemia (CLL) in COVALENT-101 Trial
From Biomea Fusion, Inc.
Via Globe NewsWire
BMF-219 Enters the Clinic for KRAS Solid Tumors
From Biomea Fusion, Inc.
Via Globe NewsWire
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Biomea Fusion Touts Additional Preclinical Data For Blood Cancer Candidate
Via Benzinga
How Is The Market Feeling About Biomea Fusion?
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday
Via Benzinga
Biomea Fusion Commences Initial-Stage Study For Plasma Cell Cancer Setting
Via Benzinga
69 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.